JP2021502386A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502386A5
JP2021502386A5 JP2020526059A JP2020526059A JP2021502386A5 JP 2021502386 A5 JP2021502386 A5 JP 2021502386A5 JP 2020526059 A JP2020526059 A JP 2020526059A JP 2020526059 A JP2020526059 A JP 2020526059A JP 2021502386 A5 JP2021502386 A5 JP 2021502386A5
Authority
JP
Japan
Prior art keywords
linker
composition according
ligase
substituent
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020526059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502386A (ja
JP7424637B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060101 external-priority patent/WO2019094772A1/en
Publication of JP2021502386A publication Critical patent/JP2021502386A/ja
Publication of JP2021502386A5 publication Critical patent/JP2021502386A5/ja
Priority to JP2024002472A priority Critical patent/JP7789402B2/ja
Application granted granted Critical
Publication of JP7424637B2 publication Critical patent/JP7424637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020526059A 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法 Active JP7424637B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024002472A JP7789402B2 (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584473P 2017-11-10 2017-11-10
US62/584,473 2017-11-10
PCT/US2018/060101 WO2019094772A1 (en) 2017-11-10 2018-11-09 Ash1l degraders and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002472A Division JP7789402B2 (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Publications (3)

Publication Number Publication Date
JP2021502386A JP2021502386A (ja) 2021-01-28
JP2021502386A5 true JP2021502386A5 (cg-RX-API-DMAC10.html) 2022-02-08
JP7424637B2 JP7424637B2 (ja) 2024-01-30

Family

ID=66432988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526068A Pending JP2021502388A (ja) 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法
JP2020526059A Active JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法
JP2024002472A Active JP7789402B2 (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020526068A Pending JP2021502388A (ja) 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024002472A Active JP7789402B2 (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Country Status (6)

Country Link
US (7) US10632209B2 (cg-RX-API-DMAC10.html)
EP (2) EP3706737B1 (cg-RX-API-DMAC10.html)
JP (3) JP2021502388A (cg-RX-API-DMAC10.html)
CN (2) CN111542318A (cg-RX-API-DMAC10.html)
CA (2) CA3082077A1 (cg-RX-API-DMAC10.html)
WO (2) WO2019094772A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414596B (zh) 2016-05-12 2023-09-29 密歇根大学董事会 Ash1l抑制剂和用其进行治疗的方法
US10632209B2 (en) * 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4029499A4 (en) * 2019-06-12 2023-07-26 Shanghaitech University Alk protein regulator and anti-tumor application thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11814373B2 (en) * 2019-09-23 2023-11-14 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
KR102325607B1 (ko) * 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
AU2021293907A1 (en) * 2020-06-17 2023-01-19 Dana-Farber Cancer Institute, Inc. Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CN113004251B (zh) * 2021-03-05 2022-09-27 郑州大学第一附属医院 含2-硝基咪唑的喹唑啉类衍生物及其应用
CN115960104A (zh) * 2021-10-09 2023-04-14 嘉兴优博生物技术有限公司 靶向蛋白酶降解(ted)平台
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
JP2025533275A (ja) * 2022-10-13 2025-10-03 ハンミ ファーマシューティカルズ カンパニー リミテッド Yap-tead相互作用を阻害するための新規なヘテロ二環式化合物及びそれを含む薬学的組成物
WO2025007905A1 (zh) * 2023-07-04 2025-01-09 西藏海思科制药有限公司 一种抑制并降解irak4的化合物的药物组合物及其在药学上的应用
US12703801B2 (en) 2023-11-01 2026-08-11 The Boeing Company Corrosion inhibition coatings with thiirane crosslinkers and methods thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861A (en) 1848-10-17 Locking umbrella and parasol
US510A (en) 1837-12-07 soeel
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US5863A (en) 1848-10-17 Matthias p
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
WO1990009381A1 (en) 1989-02-08 1990-08-23 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5391452A (en) 1993-08-02 1995-02-21 Xerox Corporation Polyester toner and developer compositions
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
BR9814340B1 (pt) * 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP4505566B2 (ja) 2004-09-30 2010-07-21 愛知県 肺癌治療剤
US20080233101A1 (en) 2005-09-15 2008-09-25 The Regents Of The University Of California RNA-mediated epigenetic regulation of gene transcription
NZ568910A (en) * 2006-01-24 2011-04-29 Lilly Co Eli Indole sulfonamide modulators of progesterone receptors
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
KR101450653B1 (ko) * 2006-07-18 2014-10-14 안티브 홀딩스 인크. 비스테로이드 항염증제의 황화수소 유도체
JP2010516291A (ja) 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性白血病(aml)の診断、予後及び治療のためのマイクロrnaに基づく方法及び組成物
AU2008240188A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
JP2010534665A (ja) 2007-07-25 2010-11-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用
WO2009051956A2 (en) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
RU2537549C2 (ru) * 2008-01-04 2015-01-10 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
EP2677865A4 (en) * 2011-02-23 2015-04-22 Icahn School Med Mount Sinai BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2014077784A1 (en) 2012-11-19 2014-05-22 Agency For Science, Technology And Research Method of treating cancer
CN105073747B (zh) * 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
WO2014151734A1 (en) * 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2015117083A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10544095B2 (en) * 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US20170158702A1 (en) 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Multivalent ras binding compounds
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
AU2017250076B2 (en) 2016-04-12 2021-07-22 The Regents Of The University Of Michigan Bet protein degraders
AU2017254702B2 (en) 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
CN109414596B (zh) * 2016-05-12 2023-09-29 密歇根大学董事会 Ash1l抑制剂和用其进行治疗的方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US10632209B2 (en) * 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
JP7123197B2 (ja) 2021-01-06 2022-08-22 エルジー ディスプレイ カンパニー リミテッド 音響発生器及び音響装置

Similar Documents

Publication Publication Date Title
JP2024041896A5 (cg-RX-API-DMAC10.html)
JP2013126982A5 (ja) 有機金属錯体及び発光材料
Lowenberg et al. Acute myeloid leukemia
JP2023523130A5 (cg-RX-API-DMAC10.html)
JP2019510066A5 (cg-RX-API-DMAC10.html)
Wei et al. The development of A3-coupling (aldehyde-alkyne-amine) and AA3-coupling (asymmetric aldehyde-alkyne-amine)
CA2924252C (en) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
JP2016501882A5 (cg-RX-API-DMAC10.html)
He et al. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL
JP2020536888A5 (cg-RX-API-DMAC10.html)
Tran et al. PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence
ES2555994T3 (es) Uso de perfiles de expresión génica para predecir la supervivencia en un paciente con cáncer
Chiang et al. Cytogenetic and molecular aberrations in endometrial stromal tumors
Vékony et al. Salivary gland carcinosarcoma: oligonucleotide array CGH reveals similar genomic profiles in epithelial and mesenchymal components
JP2006521316A5 (cg-RX-API-DMAC10.html)
JP2019529435A5 (cg-RX-API-DMAC10.html)
JP2017507175A5 (cg-RX-API-DMAC10.html)
CN110167941A (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
JP2025111617A5 (cg-RX-API-DMAC10.html)
JPWO2021220648A5 (cg-RX-API-DMAC10.html)
JP2015119721A5 (cg-RX-API-DMAC10.html)
Zhang et al. Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer
Nitzsche et al. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours
JP2020504597A5 (cg-RX-API-DMAC10.html)
Tang et al. The B-cell tumor promoter Bcl-3 suppresses inflammation-associated colon tumorigenesis in epithelial cells